^
Association details:
| Biomarker: | LDH elevation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
Published date:
05/25/2021
Excerpt:
...patients with predominantly clear cell mRCC after exactly one prior VEGF-based therapy. Patients were treated with everolimus…Responders had higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation (>27.14 nmol/L), associated with a longer median PFS (3.8 months vs. 2.2, p = 0.013)...Increased serum LDH levels two weeks after therapy initiation were the best predictor for OS...TSP-2 and LDH as promising predictive biomarkers for therapy response on everolimus after failure of one VEGF-targeted therapy in patients with clear cell mRCC.
DOI:
https://doi.org/10.3390/cancers13112594
Trial ID:
